MX2015005500A - Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. - Google Patents

Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.

Info

Publication number
MX2015005500A
MX2015005500A MX2015005500A MX2015005500A MX2015005500A MX 2015005500 A MX2015005500 A MX 2015005500A MX 2015005500 A MX2015005500 A MX 2015005500A MX 2015005500 A MX2015005500 A MX 2015005500A MX 2015005500 A MX2015005500 A MX 2015005500A
Authority
MX
Mexico
Prior art keywords
hsv
viral infections
hiv
compounds
cancer
Prior art date
Application number
MX2015005500A
Other languages
English (en)
Inventor
Raymond F Schinazi
Steven J Coats
Franck Amblard
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2015005500A publication Critical patent/MX2015005500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Abstract

La presente invención está dirigida a compuestos, composiciones y métodos para tratar o prevenir cáncer e infecciones virales, en particular, VIH, HCV, Norovirus, Saporovirus, citomegalovirus (CMV), virus herpes (HSV-1, HSV-2), virus Dengue, fiebre Amarilla, o HBV en pacientes humanos u otros huéspedes animales. Los compuestos son ciertos derivados de nucleósidos A^-hidroxicitidina, análogos de profármacos de monofosfato y fosfonatos, y sales, profármacos farmacéuticamente aceptables, y otros derivados de los mismos. En particular, los compuestos muestran una potente actividad antiviral contra VIH-1, VIH-2, HCV, Norovirus, Saporovirus, citomegalovirus (CMV), virus herpes (HSV-1, HSV-2), virus Dengue, fiebre Amarilla, y HBV.
MX2015005500A 2012-10-29 2013-10-29 Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. MX2015005500A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719696P 2012-10-29 2012-10-29
US201361763534P 2013-02-12 2013-02-12
PCT/US2013/067309 WO2014070771A1 (en) 2012-10-29 2013-10-29 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer

Publications (1)

Publication Number Publication Date
MX2015005500A true MX2015005500A (es) 2016-02-09

Family

ID=50627997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005500A MX2015005500A (es) 2012-10-29 2013-10-29 Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.

Country Status (11)

Country Link
US (1) US9809616B2 (es)
EP (1) EP2912050A4 (es)
JP (1) JP2015535261A (es)
KR (1) KR20150090894A (es)
CN (1) CN104884462A (es)
BR (1) BR112015009636A8 (es)
CA (1) CA2889717A1 (es)
HK (1) HK1214270A1 (es)
MX (1) MX2015005500A (es)
RU (1) RU2015119999A (es)
WO (1) WO2014070771A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
ES2702060T3 (es) 2011-12-22 2019-02-27 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y sus análogos
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
KR102168621B1 (ko) 2012-12-21 2020-10-22 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
US9828409B2 (en) * 2014-03-19 2017-11-28 Minghong Zhong Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
US10358458B2 (en) * 2014-09-26 2019-07-23 Riboscience Llc 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
JP6735751B2 (ja) 2014-12-15 2020-08-05 エモリー ユニバーシティー Ｂ型肝炎ウイルスの治療のためのホスホルアミデート
HRP20211456T1 (hr) * 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
WO2017156380A1 (en) * 2016-03-10 2017-09-14 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
SG11201811316YA (en) 2016-06-24 2019-01-30 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
NZ757711A (en) * 2017-03-10 2024-03-22 Lakewood Amedex Inc Antimicrobial compounds, compositions, and uses thereof
US11331331B2 (en) * 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN110075291B (zh) * 2019-02-01 2023-01-06 广州中医药大学(广州中医药研究院) 一种单磷酸类酯A缀合Tn抗肿瘤疫苗及其应用
EP3947388A4 (en) 2019-04-02 2022-12-21 Aligos Therapeutics, Inc. LINKS DIRECTED AGAINST PRMT5
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022008025A1 (en) * 2020-07-05 2022-01-13 Since & Technology Development Fund Authority 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto
WO2022218274A1 (zh) * 2021-04-15 2022-10-20 中国科学院上海药物研究所 核苷类似物及其用途
AU2022268749A1 (en) * 2021-05-06 2023-11-23 Council Of Scientific And Industrial Research A process for the preparation of n4-hydroxycytidine and its derivatives
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
WO2023025319A1 (zh) * 2021-08-27 2023-03-02 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
CN113735928A (zh) * 2021-10-21 2021-12-03 药康众拓(江苏)医药科技有限公司 一种n4-羟基胞苷衍生物及其制备方法和用途
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0355031A3 (de) 1988-08-17 1990-12-27 MATTHES, Eckart, Dr. Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
CN1081477A (zh) 1992-07-23 1994-02-02 康那香企业股份有限公司 纸纤不织布高分子吸水层的制造方法
JPH07155184A (ja) 1993-12-08 1995-06-20 Ajinomoto Co Inc 発酵法によるｌ−リジンの製造法
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
JP2005522443A (ja) 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
EP1572097A4 (en) * 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
AU2003274652A1 (en) * 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US7799908B2 (en) * 2003-01-15 2010-09-21 Valeant Pharmaceuticals North America Synthesis and use of 2′-substituted-N6 -modified nucleosides
US20050026902A1 (en) 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
CN1315863C (zh) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
DE102004051804A1 (de) 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
WO2010091386A2 (en) * 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
CN102558263A (zh) * 2010-12-28 2012-07-11 上海瑞广生化科技开发有限公司 去氧氟尿苷类衍生物,其制备方法及其制药用途

Also Published As

Publication number Publication date
RU2015119999A (ru) 2016-12-20
BR112015009636A8 (pt) 2018-04-17
KR20150090894A (ko) 2015-08-06
CA2889717A1 (en) 2014-05-08
EP2912050A4 (en) 2016-09-28
EP2912050A1 (en) 2015-09-02
US20140235566A1 (en) 2014-08-21
CN104884462A (zh) 2015-09-02
HK1214270A1 (zh) 2016-07-22
BR112015009636A2 (pt) 2017-12-12
JP2015535261A (ja) 2015-12-10
WO2014070771A1 (en) 2014-05-08
US9809616B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
MX2015005500A (es) Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.
WO2010091386A3 (en) Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
WO2012158811A3 (en) Purine monophosphate prodrugs for treatment of viral infections
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
De Clercq Antivirals: past, present and future
EA201390142A1 (ru) 2&#39;-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
EA201500304A1 (ru) Аналоги 2&#39;-хлоро нуклеозидов для инфекции вгс
EA201391519A1 (ru) 2&#39;-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
UA117095C2 (uk) Нуклеозидна сполука або її фармацевтично прийнятна сіль
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
EA201691623A1 (ru) 2&#39;-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
BR112013026219A2 (pt) análogos de n-nucleosídeo 1&#39;-substituída pirimidina para tratamento antiviral
MX2009012433A (es) Azido nucleosidos de purina para el tratamiento de infecciones virales.
WO2010118367A3 (en) Antiviral pyrimidines
EA201390141A1 (ru) 2&#39;-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
WO2010068708A3 (en) 3&#39;-azido purine nucleotide prodrugs for treatment of viral infections
EA201691118A1 (ru) Способы и соединения для лечения вирусных инфекций paramyxoviridae
GEP201706721B (en) Substituted nucleosides, nucleotides and analogs thereof
WO2011130557A3 (en) Phosphonates with reduced toxicity for treatment of viral infections
SA517382236B1 (ar) نيوكليدات بيورين مستبدلة بـ 2- n6 معدل مستبدل بــــ بيتا-d-2´-ديوكسي-2´-ألفا-فلورو-2 ´-بيتا-c لمعالجة hcv
RU2014106765A (ru) Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
EA201491180A1 (ru) 4&#39;-азидо,3&#39;-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
CR20220109A (es) Profármacos antivirales y formulaciones de los mismos
NZ628515A (en) Antiviral compounds with a dibenzooxaheterocycle moiety